Q BioMed Inc.

QBIO

US74736N1054

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 09:30:00 2024-05-23 EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.80%		0.00%	+10,025.00%

2023	Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	CI
2023	Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	CI

ISMO Tech Solutions, Inc. has Changed its Name to Q BioMed Inc

July 30, 2015 at 12:00 am

On July 30, 2015, ISMO Tech Solutions, Inc. changed its name to Q BioMed Inc.

Latest news about Q BioMed Inc.

Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-06-16	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	23-05-26	CI
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office	23-02-10	CI
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-11-03	CI
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker	22-09-27	CI
Q BioMed Inc. Reports Second Quarter Revenues in 2022	22-07-29	CI
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-28	CI
Q BioMed Inc. Announces Publication of Pre-Clinical Research Showing Superior Safety and Efficacy Against Current First Line Therapy of Its Drug Candidate Uttroside-B for Liver Cancer	22-07-26	CI
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	22-04-14	CI
Q BioMed Inc. Announces Publication of Research Showing Augmented Efficacy of its Drug Candidate Uttroside-B Against Liver Cancer	22-03-16	CI
Q BioMed Inc. Announces Initial $500,000 Order of Strontium89 to Chinese Market	22-03-07	CI
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	22-02-28	CI
Q BioMed Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Q BioMed Inc. Bolsters Commercialization of Strontium89 with EVERSANA Partnership	21-11-08	CI
Q Biomed Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	21-10-15	CI
Q BioMed Inc. announced that it has received $2.015 million in funding from GS Capital Partners LLC	21-10-04	CI
Q BioMed Inc. announced that it expects to receive $2.015 million in funding from GS Capital Partners LLC	21-09-28	CI
Q Biomed Inc. Updates on Covid-19 Therapeutic Development and Clinical Trials - Man-19 Therapeutic Program Heading to Clinical Trial in Early 2022	21-09-22	CI
Q Biomed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent in South Korea and Shows Positive Results in Initial Pre-Clinical Testing	21-08-24	CI
Q BioMed Inc. Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada	21-08-10	CI
Q BioMed Inc. announced that it has received $0.75 million in funding from Platinum Point Capital LLC	21-07-25	CI
Q Biomed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East	21-07-12	CI
Q BioMed Inc. announced that it expects to receive $20 million in funding from Aedesius Holdings Ltd	21-05-04	CI
Q Biomed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2021	21-04-14	CI
Q Biomed Awards Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs	21-03-02	CI

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Companyâs pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Q BIOMED INC.	+10,025.00%	72.55K
VERTEX PHARMACEUTICALS INCORPORATED	+11.12%	115B
REGENERON PHARMACEUTICALS, INC.	+12.73%	106B
BIONTECH SE	-4.53%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-11.80%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+7.41%	14.03B
SAREPTA THERAPEUTICS, INC.	+32.84%	12.13B